Arbutus Biopharma Corporation (ABUS) 10-Year Financial Performance & Capital Metrics

ABUS • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutArbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Show more

Revenue $6M -66.0%
EBITDA -$75M +2.3%
Net Income -$70M +4.0%
EPS (Diluted) -0.38 +13.6%
Gross Margin 100%
EBITDA Margin -1214.37% -187.2%
Operating Margin -1236.74% -187.3%
Net Margin -1133.04% -182.2%
ROE -68.76% -14.6%
ROIC -75.92% -34.2%
Debt/Equity 0.01 -83.9%
Interest Coverage -557.07 -227.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 11.8% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-8.5%

5Y0.53%

3Y-17.5%

TTM116.64%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM44.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM46.57%

ROCE

10Y Avg-55.75%

5Y Avg-50.6%

3Y Avg-51.94%

Latest-64.13%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	24.87M	1.5M	10.7M	5.9M	6.01M	6.91M	10.99M	39.02M	18.14M	6.17M
Revenue Growth %	0.66%	-0.94%	6.13%	-0.45%	0.02%	0.15%	0.59%	2.55%	-0.54%	-0.66%
Cost of Goods Sold+	51.51M	61.3M	62.7M	57.9M	57.6M	47.48M	0	0	0	0
COGS % of Revenue	2.07%	40.87%	5.86%	9.81%	9.58%	6.87%	-	-	-	-
Gross Profit+	-26.63M	-59.8M	-52M	-52M	-51.59M	-40.57M	10.99M	39.02M	18.14M	6.17M
Gross Margin %	-1.07%	-39.87%	-4.86%	-8.81%	-8.58%	-5.87%	1%	1%	1%	1%
Gross Profit Growth %	-0.12%	-1.25%	0.13%	0%	0.01%	0.21%	1.27%	2.55%	-0.54%	-0.66%
Operating Expenses+	78.53M	101.8M	80.8M	76.1M	92.31M	17.24M	84.51M	104.47M	96.24M	82.49M
OpEx % of Revenue	3.16%	67.87%	7.55%	12.9%	15.36%	2.49%	7.69%	2.68%	5.31%	13.37%
Selling, General & Admin	26.44M	39.4M	16.1M	16M	17.73M	14.85M	17.14M	17.83M	22.48M	22.11M
SG&A % of Revenue	1.06%	26.27%	1.5%	2.71%	2.95%	2.15%	1.56%	0.46%	1.24%	3.58%
Research & Development	51.51M	61.3M	62.7M	57.9M	57.6M	49.34M	65.5M	84.41M	73.7M	54.04M
R&D % of Revenue	2.07%	40.87%	5.86%	9.81%	9.58%	7.14%	5.96%	2.16%	4.06%	8.76%
Other Operating Expenses	-770K	2.5M	2.2M	7.3M	16.98M	-46.94M	1.87M	2.23M	69K	6.34M
Operating Income+	-102.32M	-491.6M	-110.9M	-89.8M	-143.9M	-57.81M	-73.52M	-65.46M	-78.1M	-76.32M
Operating Margin %	-4.11%	-327.73%	-10.36%	-15.22%	-23.94%	-8.36%	-6.69%	-1.68%	-4.31%	-12.37%
Operating Income Growth %	-2.1%	-3.8%	0.77%	0.19%	-0.6%	0.6%	-0.27%	0.11%	-0.19%	0.02%
EBITDA+	-101.73M	-490.51M	-108.87M	-87.62M	-141.87M	-55.83M	-71.77M	-64.03M	-76.7M	-74.94M
EBITDA Margin %	-4.09%	-327.01%	-10.18%	-14.85%	-23.6%	-8.07%	-6.53%	-1.64%	-4.23%	-12.14%
EBITDA Growth %	-2.13%	-3.82%	0.78%	0.2%	-0.62%	0.61%	-0.29%	0.11%	-0.2%	0.02%
D&A (Non-Cash Add-back)	589K	1.09M	2.03M	2.18M	2.03M	1.98M	1.75M	1.43M	1.4M	1.38M
EBIT	-78.9M	-489.17M	-108.47M	-61.12M	-164.27M	-59.73M	-73.39M	-63.29M	-72.39M	-69.78M
Net Interest Income+	674K	1.39M	1.28M	2.82M	3K	-3.27M	-2.73M	466K	5.23M	6.45M
Interest Income	674K	1.39M	1.54M	3M	2.11M	741K	127K	2.19M	5.69M	6.58M
Interest Expense	0	0	261K	200K	2.11M	4.01M	2.86M	1.73M	459K	137K
Other Income/Expense	25.02M	2.47M	2.2M	28.44M	-22.48M	-5.94M	-2.73M	444K	5.25M	6.4M
Pretax Income+	-77.31M	-489.1M	-108.7M	-61.4M	-166.38M	-63.74M	-76.25M	-65.01M	-72.85M	-69.92M
Pretax Margin %	-3.11%	-326.07%	-10.16%	-10.41%	-27.68%	-9.22%	-6.94%	-1.67%	-4.02%	-11.33%
Income Tax+	-16.18M	-105M	-24.3M	-4.3M	-12.66M	0	0	4.44M	0	0
Effective Tax Rate %	0.79%	0.79%	0.78%	0.93%	0.92%	1%	1%	1.07%	1%	1%
Net Income+	-61.12M	-384.1M	-84.4M	-57.1M	-153.72M	-63.74M	-76.25M	-69.46M	-72.85M	-69.92M
Net Margin %	-2.46%	-256.07%	-7.89%	-9.68%	-25.57%	-9.22%	-6.94%	-1.78%	-4.02%	-11.33%
Net Income Growth %	-0.58%	-5.28%	0.78%	0.32%	-1.69%	0.59%	-0.2%	0.09%	-0.05%	0.04%
Net Income (Continuing)	-62.72M	-384.16M	-84.41M	-57.06M	-153.72M	-63.74M	-76.25M	-69.46M	-72.85M	-69.92M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.34	-7.24	-1.54	-1.03	-2.69	-0.86	-0.73	-0.46	-0.44	-0.38
EPS Growth %	0.23%	-4.4%	0.79%	0.33%	-1.61%	0.68%	0.15%	0.37%	0.04%	0.14%
EPS (Basic)	-1.34	-7.24	-1.54	-1.03	-2.69	-0.86	-0.73	-0.46	-0.44	-0.38
Diluted Shares Outstanding	45.46M	53.05M	54.72M	55.3M	57.09M	75.84M	106.24M	150.94M	165.96M	185.61M
Basic Shares Outstanding	45.45M	53.05M	54.69M	55.3M	57.09M	75.84M	106.24M	150.94M	165.96M	185.61M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	183.88M	132.6M	129.4M	129.23M	93.83M	127.7M	160.66M	151.14M	132.03M	127.32M
Cash & Short-Term Investments	181.3M	130.5M	126.4M	124.62M	90.83M	123.27M	155.32M	146.91M	126M	122.62M
Cash Only	166.78M	23.4M	54.3M	36.94M	31.8M	52.25M	109.28M	30.78M	26.29M	36.33M
Short-Term Investments	14.53M	107.1M	72.1M	87.67M	59.03M	71.02M	46.03M	116.14M	99.72M	86.29M
Accounts Receivable	1.38M	694K	870K	1.43M	1.2M	1.31M	899K	1.35M	1.78M	2.41M
Days Sales Outstanding	20.28	168.87	29.68	88.53	73.11	69.26	29.86	12.65	35.73	142.49
Inventory	1.07M	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	7.57	-	-	-	-	-	-	-	-	-
Other Current Assets	0	293K	340K	0	0	0	0	2.87M	4.25M	2.28M
Total Non-Current Assets+	528.41M	143.3M	107.8M	98.68M	11.71M	9.38M	43.82M	44.28M	12.37M	4.39M
Property, Plant & Equipment	3.18M	6.9M	12.2M	10.14M	11.41M	9.33M	8.07M	6.81M	6.09M	4.36M
Fixed Asset Turnover	7.81x	0.22x	0.88x	0.58x	0.53x	0.74x	1.36x	5.73x	2.98x	1.42x
Goodwill	162.51M	24.4M	24.4M	22.47M	0	0	0	0	0	0
Intangible Assets	352.64M	99.4M	58.6M	43.84M	0	0	0	0	0	0
Long-Term Investments	10.07M	12.6M	12.6M	22.22M	0	0	35.69M	37.36M	6.28M	0
Other Non-Current Assets	0	12.6M	12.6M	22.22M	293K	44K	61K	103K	0	34K
Total Assets+	712.29M	275.9M	237.2M	227.91M	105.53M	137.08M	204.49M	195.42M	144.4M	131.71M
Asset Turnover	0.03x	0.01x	0.05x	0.03x	0.06x	0.05x	0.05x	0.20x	0.13x	0.05x
Asset Growth %	5.03%	-0.61%	-0.14%	-0.04%	-0.54%	0.3%	0.49%	-0.04%	-0.26%	-0.09%
Total Current Liabilities+	10.58M	10.6M	11.9M	11.24M	7.83M	9.54M	11.22M	32.86M	22.49M	15.62M
Accounts Payable	2.61M	3.21M	1.99M	3.19M	2.4M	2.99M	3.17M	3.52M	3.22M	2.32M
Days Payables Outstanding	18.5	19.14	11.57	20.12	15.2	23.02	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	372K	0	0
Deferred Revenue (Current)	868K	15K	1000K	0	0	0	0	1000K	1000K	1000K
Other Current Liabilities	4.77M	5.18M	7M	5.71M	253K	0	0	8.78M	3.7M	0
Current Ratio	17.38x	12.51x	10.87x	11.50x	11.99x	13.38x	14.32x	4.60x	5.87x	8.15x
Quick Ratio	17.28x	12.51x	10.87x	11.50x	11.99x	13.38x	14.32x	4.60x	5.87x	8.15x
Cash Conversion Cycle	9.35	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	154.03M	62.3M	42.8M	16.43M	24.96M	25.57M	23.82M	25.71M	15.9M	18.72M
Long-Term Debt	0	12M	12M	0	0	19.55M	16.3M	10.37M	6.95M	0
Capital Lease Obligations	0	0	0	0	3.02M	2.59M	2.23M	1.81M	1.34M	806K
Deferred Tax Liabilities	146.32M	41.2M	16.9M	12.66M	0	0	0	0	0	0
Other Non-Current Liabilities	7.5M	50.33M	28.06M	3.77M	2.95M	3.43M	5.3M	7.53M	7.6M	15.05M
Total Liabilities	164.61M	72.9M	54.7M	27.67M	32.79M	35.11M	35.05M	58.57M	38.38M	34.34M
Total Debt+	0	12M	12M	0	3.36M	22.54M	18.91M	12.55M	8.72M	1.29M
Net Debt	-166.78M	-11.4M	-42.3M	-36.94M	-28.44M	-29.71M	-90.37M	-18.22M	-17.56M	-35.04M
Debt / Equity	-	0.06x	0.07x	-	0.05x	0.22x	0.11x	0.09x	0.08x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-424.90x	-449.00x	-68.26x	-14.41x	-25.73x	-37.92x	-170.16x	-557.07x
Total Equity+	547.68M	203M	182.5M	200.23M	72.74M	101.97M	169.44M	136.85M	106.02M	97.37M
Equity Growth %	5.22%	-0.63%	-0.1%	0.1%	-0.64%	0.4%	0.66%	-0.19%	-0.23%	-0.08%
Book Value per Share	12.05	3.83	3.33	3.62	1.27	1.34	1.59	0.91	0.64	0.52
Total Shareholders' Equity	547.68M	203M	182.5M	200.23M	72.74M	101.97M	169.44M	136.85M	106.02M	97.37M
Common Stock	834.24M	867.39M	876.11M	879.4M	898.53M	985.94M	1.29B	1.32B	1.35B	1.41B
Retained Earnings	-266.99M	-651.15M	-738.07M	-805.22M	-970.09M	-1.05B	-1.13B	-1.2B	-1.28B	-1.35B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-49.78M	-49.78M	-48.19M	-48.17M	-48.23M	-48.17M	-48.33M	-50.49M	-48.42M	-48.13M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-54.78M	-57.88M	-48.6M	-67.9M	-71.01M	-51.44M	-67.53M	-35.36M	-85.94M	-64.85M
Operating CF Margin %	-2.2%	-38.59%	-4.54%	-11.51%	-11.81%	-7.44%	-6.15%	-0.91%	-4.74%	-10.51%
Operating CF Growth %	-3.41%	-0.06%	0.16%	-0.4%	-0.05%	0.28%	-0.31%	0.48%	-1.43%	0.25%
Net Income	-61.12M	-384.16M	-84.4M	-57.1M	-153.72M	-63.74M	-76.25M	-69.46M	-72.85M	-69.92M
Depreciation & Amortization	589K	1.09M	2.03M	2.18M	2.03M	1.98M	1.75M	1.43M	1.4M	1.38M
Stock-Based Compensation	22.09M	39.16M	15.12M	6.24M	6.8M	6.16M	6.42M	7.18M	9.3M	8.99M
Deferred Taxes	-16.18M	-105.06M	-24.32M	-4.28M	-12.66M	0	-8.18M	0	0	0
Other Non-Cash Items	14.47M	391.56M	39.83M	-10.66M	88.78M	3.73M	7.79M	-3.75M	-5.56M	-2.47M
Working Capital Changes	-14.63M	-467K	3.15M	-4.28M	-2.23M	431K	930K	29.24M	-18.23M	-2.83M
Change in Receivables	628K	735K	-129K	-1.03M	227K	-108K	413K	-453K	-424K	-633K
Change in Inventory	320K	-162K	-880K	762K	0	0	-1.91M	0	0	0
Change in Payables	-2.49M	26K	736K	-1.27M	-2.41M	1.67M	1.91M	5.22M	0	0
Cash from Investing+	7.68M	-99.12M	27.8M	-4.1M	28.34M	-14.91M	-12.68M	-74.94M	50.77M	22.95M
Capital Expenditures	-2.29M	-4M	-7.26M	-1.14M	-589K	-229K	-809K	-512K	-1.01M	-182K
CapEx % of Revenue	0.09%	2.66%	0.68%	0.19%	0.1%	0.03%	0.07%	0.01%	0.06%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	9.64M	25K	35.06M	-2.96M	11K	0	-1.81M	0	20K	0
Cash from Financing+	143.87M	12.64M	49.3M	55.6M	37.46M	86.75M	137.24M	31.81M	30.65M	52M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-10.09M	0	0	-12.14M	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.69M	637K	453K	11.47M	18.86M	449K	14.71M	11.49M	795K	7.87M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-57.07M	-61.88M	-55.86M	-69.04M	-71.59M	-51.67M	-68.34M	-35.87M	-86.94M	-65.03M
FCF Margin %	-2.29%	-41.25%	-5.22%	-11.7%	-11.91%	-7.47%	-6.22%	-0.92%	-4.79%	-10.54%
FCF Growth %	-3.23%	-0.08%	0.1%	-0.24%	-0.04%	0.28%	-0.32%	0.48%	-1.42%	0.25%
FCF per Share	-1.26	-1.17	-1.02	-1.25	-1.25	-0.68	-0.64	-0.24	-0.52	-0.35
FCF Conversion (FCF/Net Income)	0.90x	0.15x	0.58x	1.19x	0.46x	0.81x	0.89x	0.51x	1.18x	0.93x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-19.23%	-102.33%	-43.79%	-29.84%	-112.63%	-72.97%	-56.19%	-45.35%	-59.99%	-68.76%
Return on Invested Capital (ROIC)	-38.69%	-128.8%	-50.14%	-44.38%	-103.98%	-74.39%	-72.88%	-49.66%	-56.57%	-75.92%
Gross Margin	-107.07%	-3986.67%	-485.98%	-881.36%	-858.26%	-586.74%	100%	100%	100%	100%
Net Margin	-245.73%	-25606.67%	-788.79%	-967.8%	-2557.36%	-921.97%	-693.91%	-178.01%	-401.57%	-1133.04%
Debt / Equity	-	0.06x	0.07x	-	0.05x	0.22x	0.11x	0.09x	0.08x	0.01x
Interest Coverage	-	-	-424.90x	-449.00x	-68.26x	-14.41x	-25.73x	-37.92x	-170.16x	-557.07x
FCF Conversion	0.90x	0.15x	0.58x	1.19x	0.46x	0.81x	0.89x	0.51x	1.18x	0.93x
Revenue Growth	65.82%	-93.97%	613.33%	-44.86%	1.88%	15.02%	58.92%	255.11%	-53.51%	-65.98%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
License	-	-	-	-	-	-	4.67M	26M	10.7M	2.56M
License Growth	-	-	-	-	-	-	-	456.15%	-58.85%	-76.06%
Non-Cash Royalty	-	-	-	-	-	3.4M	6.11M	7.65M	3.87M	2.25M
Non-Cash Royalty Growth	-	-	-	-	-	-	79.91%	25.29%	-49.47%	-41.76%
Collaboration And Contracts	-	-	-	-	4.36M	3.52M	-	-	-	-
Collaboration And Contracts Growth	-	-	-	-	-	-19.20%	-	-	-	-
Royalty	-	-	-	154K	296.8K	-	-	-	-	-
Royalty Growth	-	-	-	-	92.73%	-	-	-	-	-
Marqibo	240K	212K	191K	-	-	-	-	-	-	-
Marqibo Growth	-	-11.67%	-9.91%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Arbutus Biopharma Corporation (ABUS) reported $14.6M in revenue for fiscal year 2024. This represents a 10% decrease from $16.3M in 2011.

Arbutus Biopharma Corporation (ABUS) saw revenue decline by 66.0% over the past year.

Arbutus Biopharma Corporation (ABUS) reported a net loss of $42.3M for fiscal year 2024.

Dividend & Returns

Arbutus Biopharma Corporation (ABUS) has a return on equity (ROE) of -68.8%. Negative ROE indicates the company is unprofitable.

Arbutus Biopharma Corporation (ABUS) had negative free cash flow of $45.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Arbutus Biopharma Corporation (ABUS) 10-Year Financial Performance & Capital Metrics

ABUS • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

Revenue $6M -66.0%
EBITDA -$75M +2.3%
Net Income -$70M +4.0%
EPS (Diluted) -0.38 +13.6%
Gross Margin 100%
EBITDA Margin -1214.37% -187.2%
Operating Margin -1236.74% -187.3%
Net Margin -1133.04% -182.2%
ROE -68.76% -14.6%
ROIC -75.92% -34.2%
Debt/Equity 0.01 -83.9%
Interest Coverage -557.07 -227.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 11.8% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-8.5%

5Y0.53%

3Y-17.5%

TTM116.64%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM44.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM46.57%

ROCE

10Y Avg-55.75%

5Y Avg-50.6%

3Y Avg-51.94%

Latest-64.13%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	24.87M	1.5M	10.7M	5.9M	6.01M	6.91M	10.99M	39.02M	18.14M	6.17M
Revenue Growth %	0.66%	-0.94%	6.13%	-0.45%	0.02%	0.15%	0.59%	2.55%	-0.54%	-0.66%
Cost of Goods Sold+	51.51M	61.3M	62.7M	57.9M	57.6M	47.48M	0	0	0	0
COGS % of Revenue	2.07%	40.87%	5.86%	9.81%	9.58%	6.87%	-	-	-	-
Gross Profit+	-26.63M	-59.8M	-52M	-52M	-51.59M	-40.57M	10.99M	39.02M	18.14M	6.17M
Gross Margin %	-1.07%	-39.87%	-4.86%	-8.81%	-8.58%	-5.87%	1%	1%	1%	1%
Gross Profit Growth %	-0.12%	-1.25%	0.13%	0%	0.01%	0.21%	1.27%	2.55%	-0.54%	-0.66%
Operating Expenses+	78.53M	101.8M	80.8M	76.1M	92.31M	17.24M	84.51M	104.47M	96.24M	82.49M
OpEx % of Revenue	3.16%	67.87%	7.55%	12.9%	15.36%	2.49%	7.69%	2.68%	5.31%	13.37%
Selling, General & Admin	26.44M	39.4M	16.1M	16M	17.73M	14.85M	17.14M	17.83M	22.48M	22.11M
SG&A % of Revenue	1.06%	26.27%	1.5%	2.71%	2.95%	2.15%	1.56%	0.46%	1.24%	3.58%
Research & Development	51.51M	61.3M	62.7M	57.9M	57.6M	49.34M	65.5M	84.41M	73.7M	54.04M
R&D % of Revenue	2.07%	40.87%	5.86%	9.81%	9.58%	7.14%	5.96%	2.16%	4.06%	8.76%
Other Operating Expenses	-770K	2.5M	2.2M	7.3M	16.98M	-46.94M	1.87M	2.23M	69K	6.34M
Operating Income+	-102.32M	-491.6M	-110.9M	-89.8M	-143.9M	-57.81M	-73.52M	-65.46M	-78.1M	-76.32M
Operating Margin %	-4.11%	-327.73%	-10.36%	-15.22%	-23.94%	-8.36%	-6.69%	-1.68%	-4.31%	-12.37%
Operating Income Growth %	-2.1%	-3.8%	0.77%	0.19%	-0.6%	0.6%	-0.27%	0.11%	-0.19%	0.02%
EBITDA+	-101.73M	-490.51M	-108.87M	-87.62M	-141.87M	-55.83M	-71.77M	-64.03M	-76.7M	-74.94M
EBITDA Margin %	-4.09%	-327.01%	-10.18%	-14.85%	-23.6%	-8.07%	-6.53%	-1.64%	-4.23%	-12.14%
EBITDA Growth %	-2.13%	-3.82%	0.78%	0.2%	-0.62%	0.61%	-0.29%	0.11%	-0.2%	0.02%
D&A (Non-Cash Add-back)	589K	1.09M	2.03M	2.18M	2.03M	1.98M	1.75M	1.43M	1.4M	1.38M
EBIT	-78.9M	-489.17M	-108.47M	-61.12M	-164.27M	-59.73M	-73.39M	-63.29M	-72.39M	-69.78M
Net Interest Income+	674K	1.39M	1.28M	2.82M	3K	-3.27M	-2.73M	466K	5.23M	6.45M
Interest Income	674K	1.39M	1.54M	3M	2.11M	741K	127K	2.19M	5.69M	6.58M
Interest Expense	0	0	261K	200K	2.11M	4.01M	2.86M	1.73M	459K	137K
Other Income/Expense	25.02M	2.47M	2.2M	28.44M	-22.48M	-5.94M	-2.73M	444K	5.25M	6.4M
Pretax Income+	-77.31M	-489.1M	-108.7M	-61.4M	-166.38M	-63.74M	-76.25M	-65.01M	-72.85M	-69.92M
Pretax Margin %	-3.11%	-326.07%	-10.16%	-10.41%	-27.68%	-9.22%	-6.94%	-1.67%	-4.02%	-11.33%
Income Tax+	-16.18M	-105M	-24.3M	-4.3M	-12.66M	0	0	4.44M	0	0
Effective Tax Rate %	0.79%	0.79%	0.78%	0.93%	0.92%	1%	1%	1.07%	1%	1%
Net Income+	-61.12M	-384.1M	-84.4M	-57.1M	-153.72M	-63.74M	-76.25M	-69.46M	-72.85M	-69.92M
Net Margin %	-2.46%	-256.07%	-7.89%	-9.68%	-25.57%	-9.22%	-6.94%	-1.78%	-4.02%	-11.33%
Net Income Growth %	-0.58%	-5.28%	0.78%	0.32%	-1.69%	0.59%	-0.2%	0.09%	-0.05%	0.04%
Net Income (Continuing)	-62.72M	-384.16M	-84.41M	-57.06M	-153.72M	-63.74M	-76.25M	-69.46M	-72.85M	-69.92M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.34	-7.24	-1.54	-1.03	-2.69	-0.86	-0.73	-0.46	-0.44	-0.38
EPS Growth %	0.23%	-4.4%	0.79%	0.33%	-1.61%	0.68%	0.15%	0.37%	0.04%	0.14%
EPS (Basic)	-1.34	-7.24	-1.54	-1.03	-2.69	-0.86	-0.73	-0.46	-0.44	-0.38
Diluted Shares Outstanding	45.46M	53.05M	54.72M	55.3M	57.09M	75.84M	106.24M	150.94M	165.96M	185.61M
Basic Shares Outstanding	45.45M	53.05M	54.69M	55.3M	57.09M	75.84M	106.24M	150.94M	165.96M	185.61M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	183.88M	132.6M	129.4M	129.23M	93.83M	127.7M	160.66M	151.14M	132.03M	127.32M
Cash & Short-Term Investments	181.3M	130.5M	126.4M	124.62M	90.83M	123.27M	155.32M	146.91M	126M	122.62M
Cash Only	166.78M	23.4M	54.3M	36.94M	31.8M	52.25M	109.28M	30.78M	26.29M	36.33M
Short-Term Investments	14.53M	107.1M	72.1M	87.67M	59.03M	71.02M	46.03M	116.14M	99.72M	86.29M
Accounts Receivable	1.38M	694K	870K	1.43M	1.2M	1.31M	899K	1.35M	1.78M	2.41M
Days Sales Outstanding	20.28	168.87	29.68	88.53	73.11	69.26	29.86	12.65	35.73	142.49
Inventory	1.07M	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	7.57	-	-	-	-	-	-	-	-	-
Other Current Assets	0	293K	340K	0	0	0	0	2.87M	4.25M	2.28M
Total Non-Current Assets+	528.41M	143.3M	107.8M	98.68M	11.71M	9.38M	43.82M	44.28M	12.37M	4.39M
Property, Plant & Equipment	3.18M	6.9M	12.2M	10.14M	11.41M	9.33M	8.07M	6.81M	6.09M	4.36M
Fixed Asset Turnover	7.81x	0.22x	0.88x	0.58x	0.53x	0.74x	1.36x	5.73x	2.98x	1.42x
Goodwill	162.51M	24.4M	24.4M	22.47M	0	0	0	0	0	0
Intangible Assets	352.64M	99.4M	58.6M	43.84M	0	0	0	0	0	0
Long-Term Investments	10.07M	12.6M	12.6M	22.22M	0	0	35.69M	37.36M	6.28M	0
Other Non-Current Assets	0	12.6M	12.6M	22.22M	293K	44K	61K	103K	0	34K
Total Assets+	712.29M	275.9M	237.2M	227.91M	105.53M	137.08M	204.49M	195.42M	144.4M	131.71M
Asset Turnover	0.03x	0.01x	0.05x	0.03x	0.06x	0.05x	0.05x	0.20x	0.13x	0.05x
Asset Growth %	5.03%	-0.61%	-0.14%	-0.04%	-0.54%	0.3%	0.49%	-0.04%	-0.26%	-0.09%
Total Current Liabilities+	10.58M	10.6M	11.9M	11.24M	7.83M	9.54M	11.22M	32.86M	22.49M	15.62M
Accounts Payable	2.61M	3.21M	1.99M	3.19M	2.4M	2.99M	3.17M	3.52M	3.22M	2.32M
Days Payables Outstanding	18.5	19.14	11.57	20.12	15.2	23.02	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	372K	0	0
Deferred Revenue (Current)	868K	15K	1000K	0	0	0	0	1000K	1000K	1000K
Other Current Liabilities	4.77M	5.18M	7M	5.71M	253K	0	0	8.78M	3.7M	0
Current Ratio	17.38x	12.51x	10.87x	11.50x	11.99x	13.38x	14.32x	4.60x	5.87x	8.15x
Quick Ratio	17.28x	12.51x	10.87x	11.50x	11.99x	13.38x	14.32x	4.60x	5.87x	8.15x
Cash Conversion Cycle	9.35	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	154.03M	62.3M	42.8M	16.43M	24.96M	25.57M	23.82M	25.71M	15.9M	18.72M
Long-Term Debt	0	12M	12M	0	0	19.55M	16.3M	10.37M	6.95M	0
Capital Lease Obligations	0	0	0	0	3.02M	2.59M	2.23M	1.81M	1.34M	806K
Deferred Tax Liabilities	146.32M	41.2M	16.9M	12.66M	0	0	0	0	0	0
Other Non-Current Liabilities	7.5M	50.33M	28.06M	3.77M	2.95M	3.43M	5.3M	7.53M	7.6M	15.05M
Total Liabilities	164.61M	72.9M	54.7M	27.67M	32.79M	35.11M	35.05M	58.57M	38.38M	34.34M
Total Debt+	0	12M	12M	0	3.36M	22.54M	18.91M	12.55M	8.72M	1.29M
Net Debt	-166.78M	-11.4M	-42.3M	-36.94M	-28.44M	-29.71M	-90.37M	-18.22M	-17.56M	-35.04M
Debt / Equity	-	0.06x	0.07x	-	0.05x	0.22x	0.11x	0.09x	0.08x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-424.90x	-449.00x	-68.26x	-14.41x	-25.73x	-37.92x	-170.16x	-557.07x
Total Equity+	547.68M	203M	182.5M	200.23M	72.74M	101.97M	169.44M	136.85M	106.02M	97.37M
Equity Growth %	5.22%	-0.63%	-0.1%	0.1%	-0.64%	0.4%	0.66%	-0.19%	-0.23%	-0.08%
Book Value per Share	12.05	3.83	3.33	3.62	1.27	1.34	1.59	0.91	0.64	0.52
Total Shareholders' Equity	547.68M	203M	182.5M	200.23M	72.74M	101.97M	169.44M	136.85M	106.02M	97.37M
Common Stock	834.24M	867.39M	876.11M	879.4M	898.53M	985.94M	1.29B	1.32B	1.35B	1.41B
Retained Earnings	-266.99M	-651.15M	-738.07M	-805.22M	-970.09M	-1.05B	-1.13B	-1.2B	-1.28B	-1.35B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-49.78M	-49.78M	-48.19M	-48.17M	-48.23M	-48.17M	-48.33M	-50.49M	-48.42M	-48.13M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-54.78M	-57.88M	-48.6M	-67.9M	-71.01M	-51.44M	-67.53M	-35.36M	-85.94M	-64.85M
Operating CF Margin %	-2.2%	-38.59%	-4.54%	-11.51%	-11.81%	-7.44%	-6.15%	-0.91%	-4.74%	-10.51%
Operating CF Growth %	-3.41%	-0.06%	0.16%	-0.4%	-0.05%	0.28%	-0.31%	0.48%	-1.43%	0.25%
Net Income	-61.12M	-384.16M	-84.4M	-57.1M	-153.72M	-63.74M	-76.25M	-69.46M	-72.85M	-69.92M
Depreciation & Amortization	589K	1.09M	2.03M	2.18M	2.03M	1.98M	1.75M	1.43M	1.4M	1.38M
Stock-Based Compensation	22.09M	39.16M	15.12M	6.24M	6.8M	6.16M	6.42M	7.18M	9.3M	8.99M
Deferred Taxes	-16.18M	-105.06M	-24.32M	-4.28M	-12.66M	0	-8.18M	0	0	0
Other Non-Cash Items	14.47M	391.56M	39.83M	-10.66M	88.78M	3.73M	7.79M	-3.75M	-5.56M	-2.47M
Working Capital Changes	-14.63M	-467K	3.15M	-4.28M	-2.23M	431K	930K	29.24M	-18.23M	-2.83M
Change in Receivables	628K	735K	-129K	-1.03M	227K	-108K	413K	-453K	-424K	-633K
Change in Inventory	320K	-162K	-880K	762K	0	0	-1.91M	0	0	0
Change in Payables	-2.49M	26K	736K	-1.27M	-2.41M	1.67M	1.91M	5.22M	0	0
Cash from Investing+	7.68M	-99.12M	27.8M	-4.1M	28.34M	-14.91M	-12.68M	-74.94M	50.77M	22.95M
Capital Expenditures	-2.29M	-4M	-7.26M	-1.14M	-589K	-229K	-809K	-512K	-1.01M	-182K
CapEx % of Revenue	0.09%	2.66%	0.68%	0.19%	0.1%	0.03%	0.07%	0.01%	0.06%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	9.64M	25K	35.06M	-2.96M	11K	0	-1.81M	0	20K	0
Cash from Financing+	143.87M	12.64M	49.3M	55.6M	37.46M	86.75M	137.24M	31.81M	30.65M	52M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-10.09M	0	0	-12.14M	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.69M	637K	453K	11.47M	18.86M	449K	14.71M	11.49M	795K	7.87M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-57.07M	-61.88M	-55.86M	-69.04M	-71.59M	-51.67M	-68.34M	-35.87M	-86.94M	-65.03M
FCF Margin %	-2.29%	-41.25%	-5.22%	-11.7%	-11.91%	-7.47%	-6.22%	-0.92%	-4.79%	-10.54%
FCF Growth %	-3.23%	-0.08%	0.1%	-0.24%	-0.04%	0.28%	-0.32%	0.48%	-1.42%	0.25%
FCF per Share	-1.26	-1.17	-1.02	-1.25	-1.25	-0.68	-0.64	-0.24	-0.52	-0.35
FCF Conversion (FCF/Net Income)	0.90x	0.15x	0.58x	1.19x	0.46x	0.81x	0.89x	0.51x	1.18x	0.93x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-19.23%	-102.33%	-43.79%	-29.84%	-112.63%	-72.97%	-56.19%	-45.35%	-59.99%	-68.76%
Return on Invested Capital (ROIC)	-38.69%	-128.8%	-50.14%	-44.38%	-103.98%	-74.39%	-72.88%	-49.66%	-56.57%	-75.92%
Gross Margin	-107.07%	-3986.67%	-485.98%	-881.36%	-858.26%	-586.74%	100%	100%	100%	100%
Net Margin	-245.73%	-25606.67%	-788.79%	-967.8%	-2557.36%	-921.97%	-693.91%	-178.01%	-401.57%	-1133.04%
Debt / Equity	-	0.06x	0.07x	-	0.05x	0.22x	0.11x	0.09x	0.08x	0.01x
Interest Coverage	-	-	-424.90x	-449.00x	-68.26x	-14.41x	-25.73x	-37.92x	-170.16x	-557.07x
FCF Conversion	0.90x	0.15x	0.58x	1.19x	0.46x	0.81x	0.89x	0.51x	1.18x	0.93x
Revenue Growth	65.82%	-93.97%	613.33%	-44.86%	1.88%	15.02%	58.92%	255.11%	-53.51%	-65.98%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
License	-	-	-	-	-	-	4.67M	26M	10.7M	2.56M
License Growth	-	-	-	-	-	-	-	456.15%	-58.85%	-76.06%
Non-Cash Royalty	-	-	-	-	-	3.4M	6.11M	7.65M	3.87M	2.25M
Non-Cash Royalty Growth	-	-	-	-	-	-	79.91%	25.29%	-49.47%	-41.76%
Collaboration And Contracts	-	-	-	-	4.36M	3.52M	-	-	-	-
Collaboration And Contracts Growth	-	-	-	-	-	-19.20%	-	-	-	-
Royalty	-	-	-	154K	296.8K	-	-	-	-	-
Royalty Growth	-	-	-	-	92.73%	-	-	-	-	-
Marqibo	240K	212K	191K	-	-	-	-	-	-	-
Marqibo Growth	-	-11.67%	-9.91%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Arbutus Biopharma Corporation (ABUS) reported $14.6M in revenue for fiscal year 2024. This represents a 10% decrease from $16.3M in 2011.

Arbutus Biopharma Corporation (ABUS) saw revenue decline by 66.0% over the past year.

Arbutus Biopharma Corporation (ABUS) reported a net loss of $42.3M for fiscal year 2024.

Dividend & Returns

Arbutus Biopharma Corporation (ABUS) has a return on equity (ROE) of -68.8%. Negative ROE indicates the company is unprofitable.

Arbutus Biopharma Corporation (ABUS) had negative free cash flow of $45.4M in fiscal year 2024, likely due to heavy capital investments.